Dr Tutuncu is a clinician, scientist, biotech executive with more than 30 years of experience in academic/medical practice and the pharmaceutical industry with specific focus on respiratory, critical care, immunology, fibrosis, orphan diseases, 505(b)2 approval pathway, and drug-device combination products.

He previously was a co-founder and CMO at Patara Pharma (acquired by, Roivant in 2018, became Respivant Sciences) and Elevation Pharma (acquired by Sunovion in 2012). Development activities led to three successful NDAs/MAAs: Flutiform pMDI and Pulmicort HFA pMDI for asthma, and Lonhala Magnair for COPD.

Dr Tutuncu received his MD/Critical Care Medicine from University of Istanbul, Turkey, and his PhD in Respiratory Pathophysiology from Erasmus University in Rotterdam, The Netherlands.